Health Care·Biotechnology·$8.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.29 | N/A | -5.45% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.29 | N/A | -5.45% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding the current financial outlook. They emphasized the importance of their clinical programs.
Management did not provide specific guidance for future performance.
The company is focusing on its ongoing clinical trials.
Cytokinetics reported a loss per share of $0.29, which was slightly below expectations. The stock fell by nearly 4% in response to the lack of revenue data and guidance. Investors may be concerned about the company's future performance without clear direction from management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CADENCE DESIGN SYS I
Jul 25, 2016